Evaluation and rehabilitation of patients with adult motor neuron disease

Archives of Physical Medicine and Rehabilitation

Volumn 80, Issue 8, 1999, Pages 951-963

  Francis, Kathleen ^a,b   Bach, John R ^a   DeLisa, Joel A ^a,c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b KESSLER INSTITUTE FOR REHABILITATION   (United States)

^c KESSLER FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; GLUTAMATE RECEPTOR ANTAGONIST; NEUROTROPHIC FACTOR; RILUZOLE; SODIUM CHANNEL BLOCKING AGENT; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL FEATURE; COMMUNICATION DISORDER; DISEASE COURSE; DYSPHAGIA; EXERCISE; FATIGUE; MOBILIZATION; MOTOR NEURON DISEASE; MYALGIA; PSYCHOSOCIAL DISORDER; RESPIRATORY FAILURE; REVIEW; SLEEP DISORDER; SURVIVAL RATE;

EID: 0032806736     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-9993(99)90089-8     Document Type: Review

References (132)

1. Williams DB, Windebank AJ. Subject review: motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin Proc 1991;66: 54-82.
2. Bradley WG. Overview of motor neuron disease: classification and nomenclature. Clin Neurosci 1996;3:323-6.
3. Strong MJ, Hudson AJ, Alvord WG. Familial amyotrophic lateral sclerosis, 1850-1989: a statistical analysis of the world literature. Can J Neurol Sci 1991;18:45-58.
4. Annegers JF, Appel S, Lee JR, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch Neurol 1991;48:589-93.
5. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain 1995;118:707-19.
6. Hudson AJ. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain 1981;104:217-47.
7. Kurtzke JF. Epidemiology of amyotrophic lateral sclerosis. Adv Neurol 1982;36:281-302.
8. Belsh JM. Epidemiology and historical perspective of ALS. In: Belsh JM, Schiffman PL, editors. Amyotrophic lateral sclerosis: diagnosis and management for the clinician. Armonk (NY): Futura Publishing Co., Inc; 1996; p. 3-8.
9. Tucker T, Layzer RB, Miller RG, Chad D. Subacute reversible motor neuron disease. Neurology 1991;41:1541-4.
10. Tsai CP, Ho HH, Yen DJ. Reversible motor neuron disease. Eur Neurol 1993;33:387-9.
11. Eisen A, Schulzer M, NacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993;16:27-32.
12. Brownell B, Oppenheimer DR, Hughes JT. The central nervous system in motor neuron disease. J Neurol Neurosurg Psychiatry 1970;33:338-57.
13. Colmant HJ. Progressive bulbar palsy in adults. In: Vinken PJ, Bruyn GW, DeJong JMBV, editors. Handbook of clinical neurology: system disorders and atrophies, Vol 22 (Part II). Amsterdam: North Holland Publishing Company; 1975. p. 111-56.
14. Pestronk A, Chaudrey V, Feldman EL. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Ann Neurol 1990;27:316-26.
15. Parry GJ, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 1988;11:103-7.
16. Fisher CM. Pure spastic paralysis of corticospinal origin. Can J Neurol Sci 1977;4:251-8.
17. Beal MF, Richardson EP. Primary lateral sclerosis: a case report. Arch Neurol 1981;38:630-3.
18. Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria. Brain 1992;115:495-520.
19. El Escorial Workshop. World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124 Suppl:96-107.
20. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
21. Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987;22:575-9.
22. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
23. Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995;4: 209-16.
24. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-8.
25. Appel SH, Smith RG, Engelhardt JL, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci 1994;124 Suppl:14-9.
26. Smith RG, Hamilton S, Hoffman F, Schneider T, Nastainczyk W, Birnbaumer L, et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 1992;327:1721-8.
27. Bergeron C. Oxidative stress: its role in the pathogenesis of amyotrophic lateral sclerosis. J Neurol Sci 1995;129 Suppl:81-4.
28. Louwerse ES, Weverling GJ, Bossuyt PM, Meyles FE, de Jong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral scerosis. Arch Neurol 1995;52:559-64.
29. Figlewicz DA, Krizus A, Martinoli MG, Meininger V, Dib M, Rouleau GA, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Human Mol Genet 1994;3:1757-61.
30. Cleveland DW. Neuronal growth and death: order and disorder in the axoplasm. Cell 1996;84:663-6.
31. Murayama S, Mori H, Ihara Y, Bouldin TW, Suzuki K, Tomonaga M. Immunohistochemical and ultrastructural studies of lower motor neurons in amyotrophic lateral sclerosis. Ann Neurol 1990;27:137-48.
32. Rothstein JD. Therapeutic horizons for amyotrophic lateral sclerosis. Curr Opin Neurobiol 1996;6:679-87.
33. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis: a study of its presentation and prognosis. J Neurol 1985;232:295-300.
34. Belsh JM. Clinical presentation and course of ALS. In: Belsh JM, Schiffman PL, editors. Amyotrophic lateral sclerosis: diagnosis and management for the clinician. Armonk (NY): Future Publishing Company, Inc.; 1996. p. 47-83.
35. Mitsumoto H. Diagnosis and progression of ALS. Neurology 1997;48 Suppl:S2-S8.
36. Munsat TL, Andres PL, Finison L, Conlon T, Thibodeau L. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 1988;38:409-13.
37. Bradley WG, Good P, Rasool CG, Adelman LS. Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis. Ann Neurol 1983;14:267-77.
38. Dyck PJ, Stevens JC, Mulder DW, Espinosa RW. Frequency of nerve fiber degeneration of peripheral motor and sensory neurons in amyotrophic lateral sclerosis. Neurology 1975;25:781-5.
39. Radtke RA, Erwin A, Erwin CW. Abnormal sensory evoked potentials in amyotrophic lateral sclerosis. Neurology 1986;36: 796-801.
40. Shefner JM, Tyler HR, Krarup C. Abnormalities in the sensory action potential on patients with amyotrophic lateral sclerosis. Muscle Nerve 1991;14:1242-6.
41. Fincham RW, Van Allan MW. Sensory nerve conduction in amyotrophic lateral sclerosis. Neurology 1964;14:31-3.
42. Kothari M, Rutkove SB, Logigian EL, Schefner JM. Coexistent entrapment neuropathies in patients with amyotrophic lateral sclerosis. Arch Phys Med Rehabil 1996;77:1186-8.
43. Mannen T, Iwata M, Toyokura Y, Nagashima K. Preservation of a certain motor neuron group in the sacral cord in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1977;40:464-9.
44. Galassi P, Montagna P, Ciardulli C, Lorusso S, Stracciara A. Cognitive impairment in motor neuron disease. Acta Neurol Scand 1985;71:480-4.
45. Poloni M, Capitani E, Mazzini L, Ceroni M. Neuropsychological measures in amyotrophic lateral sclerosis and their relationship with CT scan-assessed cerebral atrophy. Acta Neurol Scand 1986;74:257-60.
46. Ludolph AC, Langen KJ, Regard M, Herzog H, Kemper B, Kuwert T, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand 1992;85:81-9.
47. Gallagher JP. Pathological laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989;80:114-7.
48. Bocker FM, Seibold I, Neundorfer B. Disability in everyday tasks and subjective status of patients with advanced amyotrophic lateral sclerosis. Fortschritte der Neurologie Psychiatrie 1990;58: 224-36.
49. Hunter MD, Robinson IC, Neilson S. The functional and psychological status of patients with amyotrophic lateral sclero-sis: some implications for rehabilitation. Disabil Rehab 1993;15: 119-26.
50. Hogg KE, Goldstein LH, Leigh PN. The psychological impact of motor neurone disease. Psychol Med 1994;24:625-32.
51. Wilbourn AJ. Electrodiagnostic evaluation of the suspected ALS patient. In: Belsh JM, Schiffman PL, editors. Amyotrophic lateral sclerosis: diagnosis and management for the clinician. Armonk (NY): Futura Publishing Co., Inc; 1996. p. 163-202.
52. Lambert EH. Electromyography in amyotrophic lateral sclerosis. In: Norris FH, Kurland LT, editors. Motor neuron diseases: research on amyotrophic lateral sclerosis and related disorders. New York: Grune and Statton; 1969. p. 135-153.
53. Dumitru D. Central nervous system disorders. In: Dumitru D, editor. Electrodiagnostic medicine. Philadelphia: Hanley & Belfus; 1995. p. 453-521.
54. Belsh JM, Schiffman PL. Misdiagnosis in patients with amyotrophic lateral sclerosis. Arch Intern Med 1990;150:2301-5.
55. Miscio G, Pisano F, Mora G, Mazzini L. Transcranial magnetic stimulation in motor neuron disease [abstract]. Presented at the 8th International Symposium on ALS/MND; 1997 Nov 3-5; Glasgow.
56. Trefouret S, Peretti-Viton P, Azulay JPh, Pouget J. Evaluation of pyramidal tracts involvement in ALS by MRI and magnetic stimulations [abstract]. Presented at the 8th International Symposium on ALS/MND; 1997 Nov 3-5; Glasgow.
57. Eisen A, Shytbel W, Murphy K, Hoirch M. Cortical magnetic stimulation in amyotrophic lateral sclerosis. Muscle Nerve 1990; 13:146-51.
58. Caroscio JT, Mulvihill MN, Sterling R, Abrams B. Amyotrophic lateral sclerosis: Its natural history. Neurol Clin 1987;5:1-8.
59. Yorkston KM, Strand E, Miller R, Hillel A, Smith K. Speech deterioration in amyotrophic lateral sclerosis: implications for the timing of intervention. J Med Speech-Language Pathol 1993;1: 35-46.
60. Dworkin JP, Hartmann DE. Progressive speech deterioration and dysphagia in amyotrophic lateral sclerosis: case report. Arch Phys Med Rehabil 1979;60:423-5.
61. Hillel AD, Miller R. Bulbar amyotrophic lateral sclerosis: patterns of progression and clinical management. Head Neck 1989;11:51-9.
62. Kent RD, Kent JF, Weismer G. Impairment in speech intelligibility in men with amyotrophic lateral sclerosis. J Speech Hearing Disord 1990;55:721-8.
63. Kazandjian MS, editor. Communication intervention. In: Communication and swallowing solutions for the ALS/MND community. San Diego: Singular Publishing Group, Inc; 1997. p. 7-40.
64. Robbins J. Swallowing in ALS and motor neuron disorders. Neurol Clin 1987;5:213-29.
65. Slowie LA, Paige MS, Antel JP. Nutritional considerations in the management of patients with amyotrophic lateral sclerosis (ALS). J Am Diet Assoc 1983;83:44-7.
66. Kasarskis EJ, Neville HE. Management of ALS: nutritional care. Neurology 1998;47 Suppl 2:S118-20.
67. Sufit R. Symptomatic treatment of ALS. Neurology 1997;48 Suppl 4:S15-22.
68. Arora NS, Rochester DF. Respiratory muscle strength and maximal voluntary ventilation in undernourished patients. Am Rev Respir Dis 1982;126:5-8.
69. Mazzini L, Corra T, Zaccala M, Mora G, DelPiano M, Galante M. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol 1995;242:695-8.
70. Ray SA, Bundy AC, Nelson DL. Decreasing drooling through techniques to facilitate mouth closure. Am J Occup Ther 1983;37: 749-53.
71. Schiffman PL, Belsh JM. Overall management of the ALS patient. In: Belsh JM, Schiffman PL, editors. Amyotrophic lateral sclerosis: diagnosis and management for the clinician. Armonk (NY): Futura Publishing Company; 1996. p. 271-301.
72. Homburger F, Nixon CW, Eppenberger M, Baker JR. Hereditary myopathy in Syrian hamster: studies on pathogenesis. Ann N Y Acad Sci 1966;138:14-27.
73. Howells KF, Goldspink G. Effect of exercise on progress of myopathy in dystrophic hamster muscle fibers. J Anat 1974;117: 385-96.
74. Bennett RL, Knowlton GC. Overwork weakness in partially denervated skeletal muscle. Clin Orthop 1958;12:22-9.
75. Johnson EW, Braddom R. Over-work weakness in facioscapulohumeral muscular dystrophy. Arch Phys Med Rehabil 1971; 333-6.
76. deLateur BJ, Giaconi RM. Effect on maximal strength of submaximal exercise in Duchenne muscular dystrophy. Am J Phys Med 1979;58:26-36.
77. Scott OM, Hyde SA, Goddard C, Jones R, Dubowitz V. Effect of exercise in Duchenne muscular dystrophy: controlled six-month feasibility study of effects of two different regimes of exercises in children with Duchenne dystrophy. Physiotherapy 1981;67: 174-6.
78. Vignos P, Watkins M. The effect of exercise in muscular dystrophy. JAMA 1966;197:121-6.
79. Milner-Brown HS, Miller RG. Muscle strengthening through high-resistance weight training in patients with neuromuscular disorders. Arch Phys Med Rehabil 1988;69:14-9.
80. Kilmer DD, McCrory MA, Wright NC, Aitkens SG, Bernauer EM. The effect of a high resistance exercise program in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1994;75:560-3.
81. Chan CW, Sinaki M. Rehabilitation management of the ALS patient. In: Belsh JM, Schiffman PL, editors. Amyotrophic lateral sclerosis: diagnosis and management for the clinician. Armonk (NY): Futura Publishing Co., Inc; 1996. p. 315-31.
82. Fowler WM, Taylor M. Rehabilitation of muscular dystrophy and related disorders: the role of exercise. Arch Phys Med Rehabil 1982;63:319-21.
83. Brinkmann JR, Ringel SP. Effectiveness of exercise in progressive neuromuscular disease. J Neurol Rehabil 1991;5:195-9.
84. Yeung RR. The acute effects of exercise on mood state. J Psychosom Res 1996;40:123-41.
85. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-33.
86. DeLisa JA, Mikulic MA, Miller RM, Melnick RR. Amyotrophic lateral sclerosis: comprehensive management. Am Fam Physician 1979;19:137-42.
87. Sinaki M, Mulder DW. Rehabilitation techniques for patients with amyotrophic lateral sclerosis. Mayo Clin Proc 1978;53: 173-8.
88. Janiszewski DW, Caroscio JT, Wisham LH. Amyotrophic lateral sclerosis: a comprehensive rehabilitation approach. Arch Phys Med Rehabil 1983;64:304-7.
89. Fowler WM. Management of muscular dystrophy and related disorders: II. comprehensive care. Arch Phys Med Rehabil 1982;63:322-8.
90. Johnson CR. Aquatic therapy for the ALS patient. Am J Occup Ther 1988;45:115-20.
91. Gelinas D. Patient and caregiver communications and decisions. Neurology 1997;48 Suppl 4:S9-14.
92. Norris FH. Care of the amyotrophic lateral sclerosis patient. In: Mitsumoto H, Norris FH, editors. Amyotrophic lateral sclerosis: a comprehensive guide to management. New York: Demos Publications; 1994. p. 29-42.
93. Donovan WH, Carter RE, Rossi CD, Wilkerson MA. Clonidine effect on spasticity: a clinical trial. Arch Phys Med Rehabil 1988;69:193-4.
94. Young RR. Spasticity: a review. Neurology 1994;44 Suppl 9:S12-S20.
95. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 1992;77:236-40.
96. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Park B, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;320:1517-21.
97. Coffey JR, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78: 226-32.
98. Drake ME Jr. Chronic pain syndrome in amyotrophic lateral sclerosis. Arch Neurol 1983;40:453-4.
99. Kinnear W, Scriven N, Orpe V, Jefferson D. Prevalence of symptoms of sleep disturbance in patients with motor neurone disease [abstract]. Presented at the 8th International Symposium on ALS/MND; 1997 Nov 3-5; Glasgow.
100. Brooks J. Neurobehavioral aspects of ALS. In: Belsh JM, Schiffman PL, editors. Amyotrophic lateral sclerosis: diagnosis and management for the clinician. Armonk (NY): Futura Publishing Co., Inc; 1996. p. 303-13.
101. Sharma KR, Kent-Braun JA, Majumdar S, Huang Y, Mynhier M, Weiner MW, et al. Physiology of fatigue in amyotrophic lateral sclerosis. Neurology 1995;45:733-40.
102. Denys EH, Norris FH. Amyotrophic lateral sclerosis: Impairment of neuromuscular transmission. Arch Neurol 1979;36:202-5.
103. Mulder DW, Lambert EH, Eaton LM. Myasthenic syndrome in patients with amyotrophic lateral sclerosis. Neurology 1959;9: 627-31.
104. Bach JR, Saporito LR. Criteria for extubation and tracheostomy tube removal for patients with ventilatory failure: a different approach to weaning. Chest 1996;110:1566-71.
105. Leith DE. Cough. In: Brain JD, Proctor D, Reid L, editors. Lung biology in health and disease: respiratory defense mechanisms, Part 2. New York: Marcel Dekker, 1977. p. 545-92.
106. Bach JR. Amyotrophic lateral sclerosis: predictors for prolongation of life by noninvasive respiratory aids. Arch Phys Med Rehabil 1995;76:828-32.
107. Bach JR, Rajaraman R, Ballanger F, Tzeng AC, Ishikawa Y, Kulessa R, et al. Neuromuscular ventilatory insufficiency: the effect of home mechanical ventilator use vs. oxygen therapy on pneumonia and hospitalization rates. Am J Phys Med Rehabil 1998;77:8-19.
108. Bach JR. Update and perspectives on noninvasive respiratory muscle aids: part 1 - the inspiratory muscle aids. Chest 1994;105: 1230-40.
109. Bach JR. Update and perspectives on noninvasive respiratory muscle aids: part 2 - the expiratory muscle aids. Chest 1994;105: 1538-44.
110. Bach JR, Alba AS. Intermittent abdominal pressure ventilator in a regimen of noninvasive ventilatory support. Chest 1991;99: 630-6.
111. Bach JR, Alba AS, Saporito LR. Intermittent positive pressure ventilation via the mouth as an alternative to tracheostomy for 257 ventilator users. Chest 1993;103:174-82.
112. Bach JR. Mechanical insufflation-exsufflation: comparison of peak expiratory flows with manually assisted and unassisted coughing techniques. Chest 1993;104:1553-62.
113. Bach JR, Alba AS. Management of chronic alveolar hypoventilation by nasal ventilation. Chest 1990;97:52-7.
114. Houpt BL, Gould BS, Norris FH. Psychological characteristics of patients with amyotrophic lateral sclerosis (ALS). Psychosom Med 1977;39:299-303.
115. Brown WA, Mueller PS. Psychological functioning in individuals with amyotrophic lateral sclerosis (ALS). Psychosoc Med 1970; 32:141-52.
116. Schiffer RB, Babigian HM. Behavioral disorders in multiple sclerosis, temporal lobe epilepsy and amyotrophic lateral sclerosis: an epidemiological study. Arch Neurol 1984;41:1067-9.
117. Montgomery GK, Erikson LM. Neuropsychological perspectives in amyotrophic lateral sclerosis. Neurol Clin 1987;5:61-81.
118. McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA. Survival in amyotrophic lateral sclerosis: the role of psychological factors. Arch Neurol 1994;51:17-23.
119. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathological laughing and weeping with amitriptyline. N Engl J Med 1985;312: 1480-2.
120. Chaudhry SS, Bach JR. Management approaches in muscular dystrophy association clinics in 1997. Arch Phys Med Rehabil. Forthcoming.
121. Silverstein MD, Stocking CB, Antel JP, Beckwith J, Roos RP, Siegler M. Amyotrophic lateral sclerosis and life-sustaining therapy: patients' desires for information, participation in decision making, and life-sustaining therapy. Mayo Clin Proc 1991;66: 906-13.
122. Goldblatt D. Caring for patients with amyotrophic lateral sclerosis. In: Smith RA, editor. Handbook of amyotrophic lateral sclerosis. New York: Marcel Dekker, Inc; 1992. p. 271-88.
123. Bach JR. Amyotrophic lateral sclerosis: communication status and survival with ventilatory support. Am J Phys Med Rehabil 1993;72:343-9.
124. Oppenheimer EA, Baldwin-Myers A, Tanquary P. Ventilator use by patients with amyotrophic lateral sclerosis. In: Proceedings of the International Conference on Pulmonary Rehabilitation and Home Ventilation. Denver (CO): National Jewish Center; 1991. p. 49.
125. Lacomblez L, Bensimon G, Meininger V, for the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-91.
126. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-31.
127. Lange DJ, Felice KJ, Festoff BW, Gawell MJ, Gelinas DF, Kratz R, et al. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. Neurology 1996;47 Suppl 2:S93-5.
128. Borasio GD, Robberecht W, Leigh PN, Emile J, Guloff RJ, Jerusalem F, et al. A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis. European ALS/IGF-1 Study Group. Neurology 1988;51:583-6.
129. ALS CNTF Treatment Study Group. A double-blind, placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-9.
130. Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Ann Neurol 1996;39:256-60.
131. Eisen A, Stewart H, Schulzer M, Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 1993;20:297-301.
132. Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, et al. Placebo-controlled study of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1383-8.